RESUMEN
BACKGROUND: Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in the treatment of chronic hepatitis B. Bone mineral density loss has been described in TDF-treated patients with human immunodeficiency virus infection, but limited data exist for patients with chronic hepatitis B. Dual X-ray absorptiometry (DEXA) was used to determine bone mineral density changes in TDF-exposed patients. We evaluated the accuracy of the Fracture Risk Assessment Tool (FRAX) as an alternative to DEXA in clinical practice. METHODS: A total of 170 patients were studied: 122 were exposed to TDF, and 48 were controls. All patients underwent DEXA, and demographic details were recorded. FRAX scores (before and after DEXA) were calculated. RESULTS: TDF was associated with a lower hip T score (P = .02). On univariate and multivariate analysis, advancing age, smoking, lower body mass index, and TDF exposure were independent predictors of low bone mineral density. In addition, the pre-DEXA FRAX score was an accurate predictor of the post-DEXA FRAX treatment recommendation (100% sensitivity and 83% specificity), area under the curve 0.93 (95% CI, .87-.97, P < .001). CONCLUSIONS: TDF-treated patients with chronic hepatitis B have reduced bone mineral density, but the reduction is limited to 1 anatomical site. Age and advanced liver disease are additional contributing factors, underlining the importance of multifactorial fracture risk assessment. FRAX can accurately identify those at greatest risk of osteoporotic fracture.
Asunto(s)
Adenina/análogos & derivados , Densidad Ósea/efectos de los fármacos , Hepatitis B Crónica/tratamiento farmacológico , Organofosfonatos/efectos adversos , Organofosfonatos/uso terapéutico , Inhibidores de la Transcriptasa Inversa/efectos adversos , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Adenina/efectos adversos , Adenina/uso terapéutico , Adulto , Índice de Masa Corporal , Estudios Transversales , Femenino , Virus de la Hepatitis B/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Riesgo , Medición de Riesgo/métodos , TenofovirRESUMEN
A 62-year-old woman with type 1 autoimmune hepatitis (AIH) failed to sustain remission when steroids were withdrawn from a regimen of steroids and azathioprine (AZA). Thiopurine metabolites revealed elevated 6-MMP (6-methyl mercaptopurine) and low 6-TGN (6-thioguanine nucleotide) consistent with AZA-induced hepatotoxicity. Introducing the xanthine oxidase inhibitor allopurinol led to rapid normalization of alanine aminotransferase (ALT) and discontinuation of steroids.
Asunto(s)
Alopurinol/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Hepatitis Autoinmune/tratamiento farmacológico , Xantina Oxidasa/antagonistas & inhibidores , Azatioprina/uso terapéutico , Femenino , Glucocorticoides/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Persona de Mediana Edad , Prednisolona/uso terapéutico , Resultado del TratamientoRESUMEN
BACKGROUND: Insulinoma is the most common neuroendocrine neoplasm of the pancreas, characterised by hypoglycaemic symptoms. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and ethanol ablation (EUS-EA) are novel methods for treating insulinoma.We aimed to perform a systematic review to assess the efficacy and safety of EUS-guided ablation techniques for pancreatic insulinomas. METHODS: We systematically searched for articles detailing EUS-guided ablations of insulinomas. We performed a qualitative analysis and summarised data on the efficacy and safety of EUS-RFA and EUS-EA techniques. RESULTS: In total, we identified 35 case reports and case series describing 75 patients with insulinomas treatment with EUS-guided ablation. Twenty-seven patients were treated with EUS-RFA, 47 patients with EUS-EA, and 1 patient received EUS-EA and EUS-RFA in the same session. In total, 84 insulinomas were ablated (EUS-RFA: 31, EUS-EA: 53). Most insulinomas were in the head of the pancreas (40%). The clinical success rate for EUS-guided ablation techniques was 98.5%. The median glucose level was 1.95 (Q1-Q3: 1.69-2.13) mmol/L before ablation compared to 6.20 (Q1-Q3: 5.30-7.05) mmol/L after treatment. The median insulin and C-peptide levels before and after RFA/EA were 230 (Q1-Q2: 120-257) pmol/L and 41 (Q1-Q2 35-42) pmol/L; 2077 (Q1-Q2 1644-2459) pmol/L and 819 (Q1-Q2 696-1072) pmol/L, respectively. There were eleven adverse events: seven abdominal pain, two mild acute pancreatitis, one necrotising acute pancreatitis and one local hematoma. All patients recovered, and there were no periprocedural deaths. CONCLUSIONS: EUS-guided ablation of insulinoma seems to be a safe and effective treatment and is an alternative to surgical resection in selected cases.
Asunto(s)
Infecciones por Citomegalovirus/diagnóstico , Diarrea/virología , Infecciones Oportunistas/diagnóstico , Pérdida de Peso , Anciano , Colitis/diagnóstico , Enfermedad de Crohn/diagnóstico , Infecciones por Citomegalovirus/inmunología , Diagnóstico Diferencial , Diarrea/inmunología , Femenino , Humanos , Huésped Inmunocomprometido , Inmunosupresores/efectos adversos , Ácido Micofenólico/efectos adversos , Ácido Micofenólico/análogos & derivados , Infecciones Oportunistas/inmunologíaRESUMEN
INTRODUCTION: Chronic hepatitis C treatment is well described in randomized-controlled trials (RCTs). We aimed to determine whether these findings can be extrapolated to treatment programmes delivered by nurse specialists in district general hospitals (DGHs). MATERIALS AND METHODS: Within the Dorset viral hepatitis network, chronic hepatitis C patients were treated in three DGHs by nurse specialists working under the supervision of four lead clinicians. Between January 2007 and January 2012, standard of care was ribavirin and pegylated interferon-α2a administered for 24 weeks (G2/3) and 48 weeks (G1/4). Retrospective analysis of the network's database was carried out and comparisons were made with a multicentre RCT. RESULTS: In total, 242 completed patient episodes were available for analysis. Ninety per cent (219) were treatment naive. G1 patients represented 49% (107) of this cohort; 2% (six) were hepatitis B/HIV coinfected and 97% (212) were Whites. Overall, 11% (23) were lost to follow-up within 24 weeks of completing treatment. On the basis of the intention to treat, the sustained virological response rates were 45 (48/107), 60 (63/105) and 57% (4/7) for patients infected with hepatitis C virus G1, G2/3 and G4, respectively. These results are comparable with RCT data (P=0.4973, 0.1359 and 0.9552). Treatment was discontinued in 3.7% (eight) of patients because of a laboratory abnormality and 9.6% (21) because of other medical complications or side-effect intolerance. These proportions are similar to those observed in the RCT (P=0.0873 and 0.5613). CONCLUSION: Specialist nurses supported by a network of DGHs can deliver a high-quality hepatitis C service across a broad geographical area.
Asunto(s)
Antivirales/uso terapéutico , Atención a la Salud , Hepatitis C Crónica/tratamiento farmacológico , Hospitales de Distrito , Hospitales Generales , Interferón-alfa/uso terapéutico , Enfermeras Clínicas , Polietilenglicoles/uso terapéutico , Ribavirina/uso terapéutico , Adulto , Antivirales/efectos adversos , Distribución de Chi-Cuadrado , Atención a la Salud/normas , Quimioterapia Combinada , Inglaterra , Femenino , Hepatitis C Crónica/diagnóstico , Hospitales de Distrito/normas , Hospitales Generales/normas , Humanos , Interferón-alfa/efectos adversos , Masculino , Auditoría Médica , Grupo de Atención al Paciente , Seguridad del Paciente , Polietilenglicoles/efectos adversos , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Estudios Retrospectivos , Ribavirina/efectos adversos , Nivel de Atención , Factores de Tiempo , Resultado del TratamientoRESUMEN
An 18-year-old male patient with a known history of Crohn's colitis was admitted for further management of his symptoms. He was treated with anti-tumour necrosis factor (anti-TNF) adalimumab and intravenous steroids in addition to azathioprine. He developed sudden onset pleuritic chest pain. Ventilation/perfusion (V/Q) scanning was reported as normal. A computed tomography pulmonary angiogram (CTPA) showed evidence of a small peripheral wedge shaped area of consolidation in the left lower lobe. He was treated with oral antibiotics but the chest pain persisted for the next 2 weeks. A repeat chest x-ray performed 2 weeks later revealed evidence of a large hydro-pneumothorax which was promptly drained. A chest CT later showed evidence of lower lobe consolidation. Sputum cultures grew Staphylococcus aureus. It was felt that a broncho-pleural fistula due to the peripheral cavitating lesion led to the pneumothorax.
RESUMEN
We present a complicated case of extensive intra-abdominal venous thrombosis manifesting with severe central abdominal discomfort following trivial blunt local trauma and discuss the therapeutic interventions that can be used in these cases.